Pegmusirudin: Phase II data

In an open-label, U.S. Phase II trial in 127 patients, major bleeding events were rare in SPP200 and unfractionated

Read the full 197 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE